Rheumatoid arthritis
Therapeutic area
Rheumatology
Rare disease
Yes
- Definition
- A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Rheumatoid arthritis
- Therapeutic area
- Rheumatology
- rheumatoid arthritis
- RA
- rheumatoid arthritis
- Disease mechanisms
- Inflammatory
- Severity
- Moderate
- Immunology
- Rheumatology
- MONDO ID
- MONDO:0008383
- Parent condition
- MONDO:0000589
Related records
Broader conditions (16)
- Arthritic joint disease
- Arthropathy
- Autoimmune disease
- Autoimmune disorder of musculoskeletal system
- Bone disorder
- Bone inflammation disease
- Connective tissue disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Human disease
- Immune system disorder
- Inflammatory disease
- Musculoskeletal system disorder
- Rheumatic disorder
- Skeletal system disorder
Narrower conditions (10)
- Ankylosing spondylitis
- Chronic childhood arthritis
- Felty syndrome
- Juvenile ankylosing spondylitis
- Juvenile spondyloarthropathy
- Polyarticular juvenile rheumatoid arthritis
- Psoriasis-related juvenile idiopathic arthritis
- Psoriatic arthritis
- Rheumatoid arthritis-associated interstitial lung disease
- Rheumatoid vasculitis
Trials (3,256)
- "Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"
- "Learning About Biologics"-Rheumatoid Arthritis
- "Matrix Metalloproteinases 7 and 9 in Rheumatoid Arthritis Patients With Interstitial Lung Disease"
- "Translating Articular Biomarkers Into Diagnoses"
- (C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
- 10-year Follow-up of Patients With Rheumatoid Arthritis Who Received Structured Treat-to-target Therapy in Early Disease
- 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
- 12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003)
- 14-3-3η Protein, Disease Activity and Bone Mineral Density, in Female Patients With Rheumatoid Arthritis
- 14.0- 3.0- 3.0- η Protein With Rheumatoid Arthritis
- 2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis
- 2-week dc of MTX and Influenza Vaccination in RA
- 2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use
- 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
- 25-hydroxyvitamin D and Fatigue: The VITALITY Study
- 3DKnee™ System vs. the MJS Knee System
- 6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis
- 6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection
- 68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis
- 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis
Approved drugs (59)
- Abatacept
- Aceclofenac
- Adalimumab
- Anakinra
- Auranofin
- Azathioprine
- Baricitinib
- Celecoxib
- Certolizumab pegol
- Cortisone acetate
- Cyclosporine
- Dexamethasone
- Dexamethasone sodium phosphate
- Diclofenac
- Diclofenac potassium
- Diclofenac sodium
- Diflunisal
- Esomeprazole magnesium
- Etanercept
- Etodolac
Drugs in development (311)
- 2-(aminomethyl)phenol Phase 2
- ABBV-257 Phase 1
- ABBV-3373 Phase 2
- AC-430 Phase 1
- Acacia Phase 2
- Acalabrutinib Phase 2
- Acetaminophen Phase 2
- Adalimumab fosimdesonide Phase 2
- ADL-5859 Phase 2
- Afimkibart Phase 2
- AK-106 Phase 2
- Alemtuzumab Phase 1
- Amelubant Phase 2
- AMG-108 Phase 2
- Aminopterin Phase 2
- AMP-110 Phase 1
- Andecaliximab Phase 2
- Anifrolumab Phase 2
- Apilimod Phase 2
- Apilimod mesylate Phase 2
Other linked drugs (26)
- Alclofenac
- Amiprilose
- Bortezomib
- Curcumin
- Dextromethorphan hydrobromide
- Diazepam
- Dimethyl sulfoxide
- Doxycycline
- Etofenamate
- Fenoprofen
- Fosmanogepix
- Gold sodium thiomalate
- Inosine pranobex
- Magnesium oxide
- Melatonin
- Misoprostol
- Niflumic acid
- Obexelimab
- Peficitinib hydrobromide
- Raloxifene hydrochloride